Hoth Therapeutics Inc Stock Price, News & Analysis

Hoth Therapeutics (NASDAQ: HOTH) announced the initiation of enrollment and dosing for the second cohort in their Phase 1b clinical trial of BioLexa, targeting mild to moderate atopic dermatitis (eczema). This significant milestone is expected to enhance patient outcomes, with the second cohort consisting of current dermatitis patients. The trial is based in Australia, with ongoing patient enrollment. BioLexa aims to tackle chronic infections associated with Staphylococcal biofilms, leveraging a patented formulation to enhance treatment efficacy.

Hoth Therapeutics (NASDAQ: HOTH) has announced a Sponsored Research Agreement with North Carolina State University to advance its cancer treatment, HT-KIT. The study, led by Dr. Glenn Cruse, aims to optimize dosing for aggressive mast cell cancers. HT-KIT targets the cKIT receptor, crucial for cancers like gastrointestinal stromal tumors and acute myeloid leukemia. This collaboration follows Hoth's recent API and drug product manufacturing achievements, aligning with their commitment to push HT-KIT towards clinical trials.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has entered agreements with STA Pharmaceutical, a subsidiary of WuXi AppTec, for the development and manufacturing of the active pharmaceutical ingredient (API) and formulation of HT-KIT, a therapy targeting mast cell-derived cancers and anaphylaxis. The collaboration aims to expedite the production of HT-KIT, with initial small-scale material expected by Q1 2022. Following this, Hoth plans to pursue a Pre-IND meeting with the FDA.

Hoth Therapeutics (NASDAQ: HOTH) has extended its partnership with REPROCELL to study the HT-003 therapeutic platform in inflammatory bowel disease (IBD), utilizing fresh tissue from ulcerative colitis and Crohn's disease patients. The research will be conducted at REPROCELL's Centre for Predictive Drug Discovery in Glasgow. Both companies have reported promising findings regarding the therapeutic potential of HT-003, focusing on lead candidates for improved responses targeting IBD.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the Human Research Ethics Committee (HREC) approval to initiate Cohort 2 of the Phase 1b clinical trial for BioLexa Lotion, aimed at treating mild to moderate atopic dermatitis in Australia. The randomized, double-blind study will assess the safety and pharmacokinetics of BioLexa Lotion over 14 days in adult patients. Screening for Cohort 2 is set to begin this month, with the company's scientific advisors optimistic about BioLexa's potential in addressing global healthcare needs.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that its Safety Review Committee has approved the continuation of the BioLexa clinical trial following positive safety data from the first cohort of healthy subjects. No serious adverse events were reported. The company has submitted the necessary documentation to the Human Research Ethics Committee to begin dosing patients with mild to moderate atopic dermatitis. BioLexa is an antimicrobial topical formulation aimed at treating infections caused by Staphylococcal biofilms, with potential implications for chronic conditions.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the successful completion of safety results for Cohort 1 in its Phase 1b clinical trial of BioLexa, a treatment for atopic dermatitis. The trial involved healthy subjects applying BioLexa twice daily for 14 days with no serious adverse events reported. The trial is moving forward to Cohort 2, which will evaluate efficacy with patients suffering from mild to moderate atopic dermatitis. CEO Robb Knie expressed optimism about the trial's progress and future updates for investors.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) recently announced research findings from North Carolina State University regarding its therapy HT-KIT for mast cell cancers. The study shows that HT-KIT reduces mast cells by mutating mRNA, effectively halting gene proliferation associated with cancer. This treatment targets the c-KIT gene itself, rather than the mutated receptor, demonstrating potential to decrease tumor growth and improve outcomes in preclinical models. The findings are published in Molecular Therapy and underscore Hoth's commitment to innovative cancer therapies.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has initiated a preclinical study for its drug candidate HT-ALZ targeting Alzheimer's disease. The study aims to assess the impact of HT-ALZ on behavioral and pathological markers of the disease, including improvements in learning and memory in an animal model. Additionally, it will evaluate the drug's effect on non-spatial memory and the role of NK-1R blocking. This research follows a Scientific Research Agreement established in June, aiming to advance innovative therapeutic solutions.